Kowa Pharmaceuticals America
5331 Perimeter Parkway Court
Montgomery
Alabama
36116
United States
Tel: 334-288-1288
Fax: 334-288-2788
32 articles about Kowa Pharmaceuticals America
-
Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.
-
Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®
7/19/2022
Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS ® (celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate Patients.
-
CORRECTING and REPLACING Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)
6/20/2019
Kowa Pharmaceuticals America, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering drug LIVALO® (pitavastatin) for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B).
-
Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)
6/18/2019
Kowa Pharmaceuticals America, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the cholesterol-lowering drug LIVALO® (pitavastatin) for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo B).
-
Kowa Pharmaceuticals America, Inc. Enters into Co-Promotion Agreement with Allergan for BYSTOLIC® (nebivolol) in the United States
1/28/2019
Kowa Pharmaceuticals America, Inc. announced today that it has entered into an agreement with Allergan plc. to co-promote Allergan’s BYSTOLIC
-
Kowa Pharmaceuticals America, Inc. Announces Appeals Court Decision Upholding Patent Protection for LIVALO® (pitavastatin)
1/9/2019
Kowa Pharmaceuticals America, Inc. announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed the decision by the U.S. District Court for the Southern District of New York, upholding the validity of U.S. Patent No. 8,557,993 (the ‘993 patent) protecting the Company’s cholesterol-lowering drug LIVALO® (pitavastatin) tablets.
-
Kowa Pharmaceuticals America, Inc. Announces Agreement with Apotex to Resolve All Outstanding Litigation Related to Livalo (pitavastatin)
2/5/2018
Plaintiffs had brought suit against Apotex for patent infringement based on the filing of Apotex’s ANDA seeking Food and Drug Administration (FDA) approval to market 1 mg, 2 mg, and 4 mg pitavastatin calcium tablets, generic to Livalo.
-
CymaBay Therapeutics Receives $5M Milestone Payment for Arhalofenate From Kowa Pharmaceuticals America
1/8/2018
The two companied inked the deal in December 2016.
-
Kowa Pharmaceuticals America Announces Court Decision To Uphold Patent Protection For Livalo (Pitavastatin Calcium)
10/11/2017
-
Kowa Pharmaceuticals America Announces INTREPID Trial Results In The Lancet HIV Showing Superior LDL Cholesterol Reduction With LIVALO (Pitavastatin) Compared With Pravastatin In Adults With HIV And Dyslipidemia
4/19/2017
-
Kowa Pharmaceuticals America Announces Agreement With CymaBay Therapeutics To License Gout Compound
1/4/2017
-
Kowa Pharmaceuticals America Release: New Data Demonstrate Pitavastatin More Effective Than Pravastatin In Improving Inflammatory And Immune Activation Markers In HIV-Infected Patients
6/21/2016
-
Kowa Pharmaceuticals America Release: New Meta-Analysis On Pitavastatin Demonstrates No Adverse Effect Compared With Placebo Or Other Statins On New-Onset Diabetes In Non-Diabetic Patients At Risk For Cardiovascular Disease
5/4/2015
-
Kowa Pharmaceuticals America Release: Landmark Trial To Explore The Prevention Of Heart Disease In People Living With HIV
10/28/2014
-
Kowa Pharmaceuticals America Release: Data Showed After 52 Weeks, LIVALO® (Pitavastatin) 4 Mg Maintained Similar Safety And Significantly Greater LDL-C Reduction Compared With Pravastatin 40 Mg In HIV-Infected Adults With Dyslipidemia
5/1/2014
-
Amarin Corporation PLC And Kowa Pharmaceuticals America Announce U.S. Co-Promotion Agreement For Vascepa® (Icosapent Ethyl) Capsules
4/1/2014
-
Kowa Pharmaceuticals America Release: New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia
6/17/2013
-
Kowa Pharmaceuticals America Release: New Superiority Trial Showed LIVALO® (Pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults With Dyslipidemia Versus Pravastatin 40 mg
3/7/2013
-
Kowa Pharmaceuticals America, Eli Lilly and Company Release Results From a Pharmacokinetic Study
7/23/2012
-
John O'Hurley Teams Up With the National Lipid Association, Kowa Pharmaceuticals America and Eli Lilly and Company to Announce Results of Landmark Statin USAGE Survey, Largest Known Survey of Cholesterol Patients
6/19/2012